Ranolazine Refractory Angina Registry: 1-Year Results

In conclusion, ranolazine is an effective antianginal therapy in patients with RA; still at 1 year only 57% of patients remained on ranolazine because of side effects, suboptimal effectiveness, cost, or progression of disease.
Source: Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine - Category: Cardiology Tags: Original Articles Source Type: research